Stock AnalizRecursion Pharmaceuticals, Inc. RXRX
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026
Recursion Pharmaceuticals, Inc. (RXRX) is a healthcare company listed in the US with a market value of about $2.0B. In the twelve months to September 30, 2026 it had revenue of $68M and net income of -$476M, a net margin of -697.1%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 80% a year, a 5-year average ROIC of -48%.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $68M | $75M | $59M | $45M | $40M | $10M | $4M | $2M |
| Net income | -$476M | -$645M | -$464M | -$328M | -$239M | -$186M | -$87M | -$62M |
| Free cash flow | -$312M | -$378M | -$373M | -$300M | -$121M | -$198M | -$51M | -$61M |
| EPS (diluted) | $-0.86 | $-1.44 | $-1.69 | $-1.58 | $-1.36 | $-1.49 | $-3.99 | $-2.87 |
| Net margin | -697.1% | -863.4% | -788.0% | -736.0% | -601.1% | -1832.2% | -2196.0% | -2668.3% |
| ROIC | — | -53.6% | -41.8% | -67.3% | -45.8% | -30.9% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 6 analysts is $7.32, 130% above the current price; targets range from $4.00 to $10.00; the consensus rating is “Buy”; expected EPS is $-0.88 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Recursion Pharmaceuticals pay a dividend?
Not currently.
Is Recursion Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Recursion Pharmaceuticals scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.